Facts and figures




16 production sites on 5 continents.

Affiliates or offices in 77 countries.


Approximately 42,000 employees (December 2016).

Approximately 43% of employees are located in Denmark (18,221) and 57% in the rest of the world (USA: 6,128, China: 4,356, International Operations: 7,875, Europe: 4,308, Pacific: 1,558).
20% within research and development
32% in production and production administration
36% in international sales and marketing
12% in administration

Product areas

We have five product areas:
Diabetes care
Obesity and weight management
Haemophilia management
Growth hormone therapy
Hormone replacement therapy

According to applicable law, only health care professionals are allowed to access product information on our site. Please find the information under Health Care Professionals.

For patient and disease information, including pens and needles, please look under Patients.

Quarterly sale

29,572 million Danish kroner Q4 2016

Annual sale

111,780 million Danish kroner 
(Full year results 2016. See Financial Statement for more information)

Sales by business segment
Q4 2016

Diabetes and obesity care 23,827 million Danish kroner

Biopharmaceuticals 5,745 million Danish kroner

Sales by region
Q4 2016

USA: 15,343 million Danish kroner
Europe: 5,275 million Danish kroner
International Operations: 3,877 million Danish kroner
Region China: 2,540 million Danish kroner
Pacific:  2,537 million Danish kroner


Novo Nordisk A/S

Bagsværd, Denmark, 
CVR nr. 24 25 67 90



Financial highlights

Download annual reports, interim reports,
investor presentations and more.

Download centre

Share information

Learn more about Novo Nordisk shares.

Shareholder rights

Novo Nordisk products

Facts about Novo Nordisk products

Product facts